An estimated 16 million people in the United States have a formal dry eye disease (DED) diagnosis, yet experts know the condition is notoriously underdiagnosed.
Hear from Drs. Nichols & O'Dell as they share their insight and expertise into the complexities of meibomian gland dysfunction-related DED and the best approach for diagnosing and treating each patient.
This activity is supported by an unrestricted educational grant from Bausch + Lomb.
Upon completion of this activity, the participant should be able to:
Sponsored by 
Evolve Medical Education LLC (Evolve) is a COPE-accredited administrator.
This virtual webinar, COPE Activity Number 124316, is accredited by COPE for continuing education for optometrists for 1.5 hours.
Course ID: 79232-TD
Activity ID: 124316
COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Kelly K. Nichols, OD, MPH, PhD, FAAO
Professor and Dean
University of Alabama at Birmingham
School of Optometry
Birmingham, AL
Leslie O’Dell, OD, FAAO
Medical Director
Director of Clinical Research
Medical Optometry America
York, PA
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Kelly K. Nichols, OD, MPH, PhD, FAAO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Aerie Pharmaceuticals, Alderya, Allergan/AbbVie, Axim, Bausch + Lomb, Bruder Healthcare, Dompé, HanAll Bio, Kala Pharmaceuticals, Novartis, Osmotica/RVL, Oyster Point Pharma, Palatin, Sight Sciences, Sun Pharmaceutical Industries, Tarsus Pharmaceuticals, Tear Film Innovations/Alcon, TearSolutions, Thea, TopiVert, Versea Visionology, Xequel, and YuYu Pharma. Grant/Research: Allergan/AbbVie, Aramis, Kala Pharmaceuticals, Kowa, ScienceBased Health, Sylentis, and Tear Science. Stock/Shareholder: Visionology.
Leslie O’Dell, OD, FAAO, has had a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Alcon, Alderya, Allergan, Bausch + Lomb, EyeDetech, Eye Eco, Johnson & Johnson Vision, Kala Pharmaceuticals, Novartis, Ocuphire, Oyster Point, Sight Sciences, Sun Pharmaceutical Industries, and Tarsus Pharmaceuticals. Speaker's Bureau: Aerie Pharmaceuticals, Alcon, Allergan/AbbVie, Bausch + Lomb, Kala Pharmaceuticals, Oyster Point Pharma, and Sun Pharmaceutical Industries. Stock/Shareholder: Eyes are the Story, EyeDetech, and Medical Optometry America.
The Evolve staff, planners, and reviewers have no financial relationships with ineligible companies.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Bausch + Lomb.
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Douglas K. Devries, OD
Cecelia Koetting, OD, FAAO
Douglas K. Devries, OD
Cecelia Koetting, OD, FAAO
Douglas K. Devries, OD
Cecelia Koetting, OD, FAAO
Douglas K. Devries, OD
Cecelia Koetting, OD, FAAO
